Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Uldrick Website

Thomas S. Uldrick, M.D.

Selected Publications

1)  Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R.
An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
Clin. Infect. Dis. 51: 350-8, 2010.
[Journal]
2)  Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Blood. 117: 6977-86, 2011.
[Journal]
3)  Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.
Phase II study of bevacizumab in patients with HIV-associated Kaposi"s sarcoma receiving antiretroviral therapy.
J. Clin. Oncol. 30: 1476-83, 2012.
[Journal]
4)  Uldrick TS, Pipkin S, Scheer S, Hessol NA.
Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma.
AIDS. 28: 397-405, 2014.
[Journal]
5)  Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM.
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
J. Acquir. Immune Defic. Syndr. 60: 150-7, 2012.
[Journal]
6)  Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
J Pharm Biomed Anal. 92: 63-8, 2014.
[Journal]
7)  Polizzotto MN, Uldrick TS, Yarchoan R.
Case 29-2013: An HIV-positive man with dyspnea and skin lesions.
N. Engl. J. Med. 370: 87-8, 2014.
[Journal]
8)  Venkataraman G, Uldrick TS, Aleman K, O'Mahony D, Karcher DS, Steinberg SM, Raffeld MA, Marshall V, Whitby D, Little RF, Yarchoan R, Pittaluga S, Maric I.
Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Am. J. Clin. Pathol. 139: 651-61, 2013.
[Journal]
9)  Kainerstorfer JM, Polizzotto MN, Uldrick TS, Rahman R, Hassan M, Najafizadeh L, Ardeshirpour Y, Wyvill KM, Aleman K, Smith PD, Yarchoan R, Gandjbakhche AH.
Evaluation of non-invasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma.
PLoS ONE. 8: e83887, 2013.
[Journal]
10)  Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R.
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Blood. 2013.
[Journal]
11)  Dong HY, Wang W, Uldrick TS, Gangi M.
Human herpesvirus 8- and Epstein-Barr virus-associated solitary B cell lymphoma with a T cell immunophenotype.
Leuk. Lymphoma. 54: 1560-3, 2013.
[Journal]
12)  de Witt P, Maartens DJ, Uldrick TS, Sissolak G.
Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
J. Acquir. Immune Defic. Syndr. 64: 66-73, 2013.
[Journal]
13)  Uldrick TS, Polizzotto MN, Yarchoan R.
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Curr Opin Oncol. 24: 495-505, 2012.
[Journal]
14)  Mosam A, Uldrick TS, Shaik F, Carrara H, Aboobaker J, Coovadia H.
An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa.
Int J STD AIDS. 22: 671-3, 2011.
[Journal]
15)  Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA.
Cancer burden in the HIV-infected population in the United States.
J. Natl. Cancer Inst. 103: 753-62, 2011.
[Journal]
16)  Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, Zheng ZM.
Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation.
J. Pathol. 225: 378-89, 2011.
[Journal]
17)  Uldrick TS, Whitby D.
Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.
Cancer Lett. 305: 150-62, 2011.
[Journal]
18)  Abend JR, Uldrick T, Ziegelbauer JM.
Regulation of TWEAKR expression by KSHV microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression.
Journal of virology. 2010.
[Journal]
19)  Mosam A, Carrara H, Shaik F, Uldrick T, Berkman A, Aboobaker J, Coovadia HM.
Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006).
International journal of STD & AIDS. 20: 553-6, 2009.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.